Hims & Hers Health (HIMS) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Hims & Hers published the results on November 9, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Hims & Hers acquired Eucalyptus, an Australian digital health platform, in June 2026 for an accounting purchase price of $968.5 million. Eucalyptus is the main reason Rest of the World Revenue rose 321%.
• Hims & Hers reports no adjusted EPS. Its non-GAAP measures are Adjusted EBITDA and Free Cash Flow.

Source: Hims & Hers Q3 2026 results, November 9, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Hims & Hers splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Hims & Hers's United States Revenue revenue was $657 million in Q3 2026, up 21% from $544 million in Q3 2025, 74% of total revenue.
• Hims & Hers's Rest of the World Revenue revenue was $233 million in Q3 2026, up 321% from $55.5 million in Q3 2025, 26% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

The first two lines are Hims & Hers' outlook for Q4 2026, the last two for the full year 2026.

In its Q3 2026 release, Hims & Hers said:

“Revenue of $875 million to $895 million.”

“Adjusted EBITDA of $70 million to $90 million, reflecting an Adjusted EBITDA margin of 8% to 10%.”

“Revenue of $3.13 billion to $3.15 billion.”

“Adjusted EBITDA of $257 million to $277 million, reflecting an Adjusted EBITDA margin of 8% to 9%.”

Source: Hims & Hers Q3 2026 release, Nov 9, 2026.

This is the company's own guidance as of Nov 9, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the HIMS forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP revenue and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Hims & Hers's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 9, 2026

Hims & Hers reported Q3 2026 revenue of $890.4 million, up 49% from $599.0 million. United States Revenue was $657.1 million, up 21%, and Rest of the World Revenue was $233.3 million, up 321% from $55.5 million. (Hims & Hers Q3 2026 release, Nov 9, 2026; Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

Hims & Hers' 10-Q attributes the international jump primarily to geographic expansion from recent acquisitions, including Eucalyptus, which closed in June 2026. Eucalyptus is a digital health platform headquartered in Australia with operations in Australia, the United Kingdom, Germany, Ireland, Canada and Japan; the accounting purchase price was $968.5 million. (Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

In the United States, growth came primarily from the Hers brand on weight loss and dermatology offerings, including more branded weight loss offerings, partly offset by a shift to shorter shipping cadences that changed the timing of revenue recognition. Hers represented approximately 45% of United States Revenue in Q3 2026, against approximately 40% a year earlier, and a majority of United States Revenue came from non-GLP-1 offerings. (Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

Hims & Hers sells subscriptions to treatments prescribed through its platform for conditions including sexual health, hair loss, hormone health, weight loss, dermatology and mental health. Subscribers reached 2,788 thousand at September 30, 2026, up 13%, and monthly revenue per average subscriber rose to $105 from $81, which the 10-Q attributes to product mix, including weight loss uptake, and the Eucalyptus acquisition. (Hims & Hers Form 10-K, 2025, Feb 23, 2026; Hims & Hers Q3 2026 release, Nov 9, 2026; Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

Hims & Hers reported a GAAP net loss of $33.0 million, or $(0.14) per diluted share, against net income of $15.8 million, or $0.06, in Q3 2025. Gross margin fell to 57% from 74%, which the 10-Q attributes primarily to weight loss offerings with shorter shipping cadences and higher fulfillment costs, plus international growth, new offerings and recent acquisitions. (Hims & Hers Q3 2026 release, Nov 9, 2026; Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

Hims & Hers does not report an adjusted EPS. Its Adjusted EBITDA of $82.4 million adds back stock-based compensation of $64.5 million, depreciation and amortization of $38.2 million, and acquisition, transaction and investment earn-out costs of $35.4 million, among other items. Marketing expenses rose 7% to $247.3 million. (Hims & Hers Q3 2026 release, Nov 9, 2026; Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted weighted average shares were 233,821,898, the same as basic shares because of the loss, against 248,675,710 a year earlier. The 10-Q records $3.8 million of restructuring charges in the quarter tied to the change in its United States weight loss offering toward branded GLP-1 medications. (Hims & Hers Q3 2026 release, Nov 9, 2026; Hims & Hers Form 10-Q, Q3 2026, Nov 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Hims & Hers gives quarterly and full-year guidance in its release. For Q4 2026 it expects revenue of $875 million to $895 million and Adjusted EBITDA of $70 million to $90 million. It tightened full-year 2026 revenue guidance to $3.13 billion to $3.15 billion and reduced Adjusted EBITDA guidance to $257 million to $277 million. (Hims & Hers Q3 2026 release, Nov 9, 2026)

Hims & Hers does not reconcile forward-looking Adjusted EBITDA to net income or loss, citing components it cannot predict with reasonable certainty. Its CFO said marketing spend was being paced ahead of several planned platform expansions in the fourth quarter. (Hims & Hers Q3 2026 release, Nov 9, 2026)

A consensus figure is the average of the models published by the analysts who cover Hims & Hers, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Hims & Hers's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning HIMS is on is HIMS a buy or a sell?, what analysts expect next is on the HIMS forecast, and what the company does is on the Hims & Hers Health (HIMS) stock page.

Every number on this page can be traced to a document Hims & Hers published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.